Literature DB >> 2760480

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs.

J M Katz1, R G Webster.   

Abstract

Influenza virus (H3N2) host cell variants isolated from a single infected individual were compared for their protective efficacies when used as formalin-inactivated purified whole virus vaccines in ferrets. A/Mem/12/85 virus grown in embryonated chicken eggs (egg-grown), which differs from A/Mem/12/85 grown in mammalian Madin-Darby canine kidney cells (MDCK-grown) by a single amino acid substitution in the hemagglutinin molecule, was shown to be distinguishable by immune ferret serum. Ferrets were immunized intramuscularly with intact inactivated MDCK- or egg-grown virus and were subsequently challenged with infectious virus grown in either host cell type. MDCK-grown-virus vaccine induced higher mean serum hemagglutination-inhibiting (HAI) and neutralizing antibody titers than did egg-grown-virus vaccine and induced superior protection of ferrets against subsequent challenge with infectious virus grown in either host cell type. These results suggest that human influenza viruses that are antigenically and structurally similar to viruses grown in mammalian cells may be more efficacious as vaccines than some variants selected in eggs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2760480     DOI: 10.1093/infdis/160.2.191

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  40 in total

1.  Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs.

Authors:  I V Alymova; S Kodihalli; E A Govorkova; B Fanget; C Gerdil; R G Webster
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 2.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination.

Authors:  Feng Liu; F Liaini Gross; Stacie N Jefferson; Crystal Holiday; Yaohui Bai; Li Wang; Bin Zhou; Min Z Levine
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

4.  Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus.

Authors:  J M Katz; M Wang; R G Webster
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

Review 5.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

6.  Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response.

Authors:  Baidong Hou; Philippe Saudan; Gary Ott; Matthew L Wheeler; Ming Ji; Lili Kuzmich; Linda M Lee; Robert L Coffman; Martin F Bachmann; Anthony L DeFranco
Journal:  Immunity       Date:  2011-02-25       Impact factor: 31.745

Review 7.  Cell-based influenza vaccines: progress to date.

Authors:  Jennifer M Audsley; Gregory A Tannock
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Authors:  Aseem Pandey; Neetu Singh; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Hum Vaccin       Date:  2010-02-24

9.  Influenza A virus lacking M2 protein as a live attenuated vaccine.

Authors:  Shinji Watanabe; Tokiko Watanabe; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2009-03-25       Impact factor: 5.103

10.  MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.

Authors:  Joost H C M Kreijtz; Yasemin Suezer; Gerrie de Mutsert; Geert van Amerongen; Astrid Schwantes; Judith M A van den Brand; Ron A M Fouchier; Johannes Löwer; Albert D M E Osterhaus; Gerd Sutter; Guus F Rimmelzwaan
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.